GRFS Grifols
- 6.940
- +0.100+1.46%
- 6.920
- -0.020-0.29%
Grifols News
European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading
European equities traded in the US as American depositary receipts rose late Thursday morning, gaining 0.35% to 1,403.4 on the S&P Europe Select ADR Index. From continental Europe, the gainers were le
Short Seller Gains 31% on Grifols That Tripped Elliott Spinout
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Wednesday Trading
European equities traded in the US as American depositary receipts were trending modestly higher late Wednesday morning, rising 0.34% to 1,399.71 on the S&P Europe Select ADR Index. From continental E
European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading
European equities traded in the US as American depositary receipts started the week off on a positive note, rising 0.42% to 1,380.39 on the S&P Europe Select ADR Index. From continental Europe, the ga
Grifols Expects June Completion of Haier Group Deal
Grifols (GRF.MC) said Monday that the sale of its 20% stake in blood products company Shanghai RAAS to Chinese home appliance company Haier Group is expected to be completed by June. The Spanish pharm
Grifols And Haier Completed Domestic And Overseas Government Approval Procedures For 20% Stake Transfer Of SRAAS
Grifols And Haier Completed Domestic And Overseas Government Approval Procedures For 20% Stake Transfer Of SRAAS
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Set to Close Week Lower
European equities traded in the US as American depositary receipts were trending modestly higher Friday morning, rising 0.42% to 1,371.48 on the S&P Europe Select ADR Index. Despite the gain, the inde
European Equities Traded in the US as American Depositary Receipts Rise Modestly Higher in Thursday Trading
European equities traded in the US as American depositary receipts were trending modestly higher Thursday morning, rising 0.25% to 1,364.91 on the S&P Europe Select ADR Index. From continental Europe,
European Equities Traded in the US as American Depositary Receipts Trend Modestly Lower in Wednesday Trading
European equities traded in the US as American depositary receipts were trending modestly lower Wednesday morning, declining 0.36% to 1,359.56 on the S&P Europe Select ADR Index. From continental Euro
Grifols Issues EUR1 Billion Notes Due 2030
Grifols (GRF.MC) said Tuesday it issued 1 billion euros of 7.5% senior secured notes due May 2030. Proceeds from the issuance will be used for the redemption of senior unsecured notes due May 2025 iss
Global Pulmonary Drugs Market Is Expected to Showcase a Significant Growth by 2030, Predicts DelveInsight | Key Companies - F. Hoffmann-La Roche, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Sanofi, Grifols, Regeneron
New York, USA, April 25, 2024 (GLOBE NEWSWIRE) -- Global Pulmonary Drugs Market is Expected to Showcase a Significant Growth by 2030, Predicts DelveInsight | Key Companies - F. Hoffmann-La Roche, AstraZeneca,
European Equities Traded in the US as American Depositary Receipts Jump in Tuesday Trading
European equities traded in the US as American depositary receipts jumped Tuesday morning, advancing 1.31% to 1,362.51 on the S&P Europe Select ADR Index. From continental Europe, the gainers were led
Grifols to Launch EUR1 Billion Note Offering
Grifols (GRF.MC) is set to launch a private offering of 1 billion euros of 7.5% senior secured notes due April 2030 for the redemption of senior unsecured notes due May 2025. The Spanish pharmaceutica
Grifols Achieves Results From Phase 4 Study Of Fanhdi In Patients With Von Willebrand Disease
Grifols Achieves Results From Phase 4 Study Of Fanhdi In Patients With Von Willebrand Disease
Grifols SA's Related Party Transactions: Navigating Conflicts of Interest and Investor Concerns
Grifols 2023 Annual Report on Form 20-F Filed With the SEC
BARCELONA, Spain, April 19, 2024 /PRNewswire/ -- Grifols, S.A. ("Grifols") (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines, toda
Myasthenia Gravis (MG) Treatment Industry Forecast to 2030: A $2.5 Billion Market Dominated by Alexion Pharma, Grifols, Avadel Pharma, Novartis, Pfizer, AbbVie, and Roche
Grifols Reportedly Looking to Appoint Independent Directors
Market Chatter: Grifols Plans to Appoint Independent Directors Only to Audit, Compensation Committees
Grifols (GRFS) is planning to appoint independent directors only to its audit and compensation committees as part of measures to continue enhancing governance, La Vanguardia reported, citing an interv
323 drugs, hurry up! America is facing the biggest “drug shortage” in history...
The US now seems to be facing an unprecedented “drug shortage”...
Analysis
Price Target
No Data
